vs

Side-by-side financial comparison of Orchestra BioMed Holdings, Inc. (OBIO) and Penumbra Inc (PEN). Click either name above to swap in a different company.

Penumbra Inc is the larger business by last-quarter revenue ($385.4M vs $30.9M, roughly 12.5× Orchestra BioMed Holdings, Inc.). Orchestra BioMed Holdings, Inc. runs the higher net margin — 20.2% vs 12.3%, a 7.9% gap on every dollar of revenue. On growth, Orchestra BioMed Holdings, Inc. posted the faster year-over-year revenue change (12120.2% vs 22.1%). Penumbra Inc produced more free cash flow last quarter ($68.0M vs $-2.3M). Over the past eight quarters, Orchestra BioMed Holdings, Inc.'s revenue compounded faster (606.2% CAGR vs 17.6%).

Orchestra BioMed Holdings, Inc. is a clinical-stage medical technology company focused on developing novel, evidence-based therapeutic solutions for cardiovascular and other high-burden chronic diseases. It collaborates with leading healthcare stakeholders, operates primarily across North American and European markets, with core segments covering interventional cardiology and chronic disease care optimization.

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.

OBIO vs PEN — Head-to-Head

Bigger by revenue
PEN
PEN
12.5× larger
PEN
$385.4M
$30.9M
OBIO
Growing faster (revenue YoY)
OBIO
OBIO
+12098.0% gap
OBIO
12120.2%
22.1%
PEN
Higher net margin
OBIO
OBIO
7.9% more per $
OBIO
20.2%
12.3%
PEN
More free cash flow
PEN
PEN
$70.4M more FCF
PEN
$68.0M
$-2.3M
OBIO
Faster 2-yr revenue CAGR
OBIO
OBIO
Annualised
OBIO
606.2%
17.6%
PEN

Income Statement — Q4 2025 vs Q4 2025

Metric
OBIO
OBIO
PEN
PEN
Revenue
$30.9M
$385.4M
Net Profit
$6.2M
$47.3M
Gross Margin
99.8%
68.0%
Operating Margin
21.8%
15.4%
Net Margin
20.2%
12.3%
Revenue YoY
12120.2%
22.1%
Net Profit YoY
138.7%
40.6%
EPS (diluted)
$0.28
$1.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OBIO
OBIO
PEN
PEN
Q4 25
$30.9M
$385.4M
Q3 25
$861.0K
$354.7M
Q2 25
$836.0K
$339.5M
Q1 25
$868.0K
$324.1M
Q4 24
$253.0K
$315.5M
Q3 24
$987.0K
$301.0M
Q2 24
$778.0K
$299.4M
Q1 24
$620.0K
$278.7M
Net Profit
OBIO
OBIO
PEN
PEN
Q4 25
$6.2M
$47.3M
Q3 25
$-20.8M
$45.9M
Q2 25
$-19.4M
$45.3M
Q1 25
$-18.8M
$39.2M
Q4 24
$-16.2M
$33.7M
Q3 24
$-15.4M
$29.5M
Q2 24
$-16.0M
$-60.2M
Q1 24
$-13.5M
$11.0M
Gross Margin
OBIO
OBIO
PEN
PEN
Q4 25
99.8%
68.0%
Q3 25
94.3%
67.8%
Q2 25
94.5%
66.0%
Q1 25
94.9%
66.6%
Q4 24
77.1%
66.8%
Q3 24
93.1%
66.5%
Q2 24
94.3%
54.4%
Q1 24
94.5%
65.0%
Operating Margin
OBIO
OBIO
PEN
PEN
Q4 25
21.8%
15.4%
Q3 25
-2359.2%
13.8%
Q2 25
-2311.8%
12.0%
Q1 25
-2179.8%
12.4%
Q4 24
-6591.7%
13.6%
Q3 24
-1655.7%
11.7%
Q2 24
-2167.0%
-27.0%
Q1 24
-2326.3%
4.3%
Net Margin
OBIO
OBIO
PEN
PEN
Q4 25
20.2%
12.3%
Q3 25
-2419.0%
12.9%
Q2 25
-2316.1%
13.3%
Q1 25
-2160.7%
12.1%
Q4 24
-6385.4%
10.7%
Q3 24
-1562.9%
9.8%
Q2 24
-2054.0%
-20.1%
Q1 24
-2171.5%
3.9%
EPS (diluted)
OBIO
OBIO
PEN
PEN
Q4 25
$0.28
$1.20
Q3 25
$-0.40
$1.17
Q2 25
$-0.50
$1.15
Q1 25
$-0.49
$1.00
Q4 24
$-0.42
$0.88
Q3 24
$-0.41
$0.75
Q2 24
$-0.45
$-1.55
Q1 24
$-0.38
$0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OBIO
OBIO
PEN
PEN
Cash + ST InvestmentsLiquidity on hand
$106.5M
$186.9M
Total DebtLower is stronger
$15.0M
Stockholders' EquityBook value
$53.6M
$1.4B
Total Assets
$114.9M
$1.8B
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OBIO
OBIO
PEN
PEN
Q4 25
$106.5M
$186.9M
Q3 25
$95.8M
$321.0M
Q2 25
$33.9M
$421.8M
Q1 25
$49.9M
$376.1M
Q4 24
$66.8M
$324.4M
Q3 24
$66.9M
$280.5M
Q2 24
$65.2M
$288.3M
Q1 24
$75.0M
$223.1M
Total Debt
OBIO
OBIO
PEN
PEN
Q4 25
$15.0M
Q3 25
$15.0M
Q2 25
$15.0M
Q1 25
$15.0M
Q4 24
$15.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
OBIO
OBIO
PEN
PEN
Q4 25
$53.6M
$1.4B
Q3 25
$43.7M
$1.4B
Q2 25
$295.0K
$1.3B
Q1 25
$16.9M
$1.2B
Q4 24
$33.0M
$1.2B
Q3 24
$46.2M
$1.1B
Q2 24
$44.1M
$1.2B
Q1 24
$57.2M
$1.2B
Total Assets
OBIO
OBIO
PEN
PEN
Q4 25
$114.9M
$1.8B
Q3 25
$104.8M
$1.7B
Q2 25
$42.8M
$1.7B
Q1 25
$59.1M
$1.6B
Q4 24
$76.2M
$1.5B
Q3 24
$75.3M
$1.5B
Q2 24
$72.4M
$1.5B
Q1 24
$82.6M
$1.6B
Debt / Equity
OBIO
OBIO
PEN
PEN
Q4 25
0.28×
Q3 25
0.34×
Q2 25
50.85×
Q1 25
0.89×
Q4 24
0.46×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OBIO
OBIO
PEN
PEN
Operating Cash FlowLast quarter
$-2.3M
$86.5M
Free Cash FlowOCF − Capex
$-2.3M
$68.0M
FCF MarginFCF / Revenue
-7.4%
17.7%
Capex IntensityCapex / Revenue
0.1%
4.8%
Cash ConversionOCF / Net Profit
-0.36×
1.83×
TTM Free Cash FlowTrailing 4 quarters
$-49.5M
$174.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OBIO
OBIO
PEN
PEN
Q4 25
$-2.3M
$86.5M
Q3 25
$-14.6M
$58.3M
Q2 25
$-15.5M
$44.9M
Q1 25
$-16.6M
$49.0M
Q4 24
$-13.5M
$51.1M
Q3 24
$-13.7M
$56.5M
Q2 24
$-10.2M
$22.6M
Q1 24
$-13.1M
$38.3M
Free Cash Flow
OBIO
OBIO
PEN
PEN
Q4 25
$-2.3M
$68.0M
Q3 25
$-14.9M
$42.0M
Q2 25
$-15.6M
$29.4M
Q1 25
$-16.7M
$35.5M
Q4 24
$-13.6M
$45.7M
Q3 24
$-13.8M
$51.0M
Q2 24
$-10.3M
$18.1M
Q1 24
$-13.1M
$32.5M
FCF Margin
OBIO
OBIO
PEN
PEN
Q4 25
-7.4%
17.7%
Q3 25
-1725.9%
11.8%
Q2 25
-1861.4%
8.7%
Q1 25
-1927.2%
11.0%
Q4 24
-5392.9%
14.5%
Q3 24
-1394.9%
16.9%
Q2 24
-1325.6%
6.0%
Q1 24
-2116.5%
11.7%
Capex Intensity
OBIO
OBIO
PEN
PEN
Q4 25
0.1%
4.8%
Q3 25
36.0%
4.6%
Q2 25
4.1%
4.6%
Q1 25
12.9%
4.2%
Q4 24
41.9%
1.7%
Q3 24
6.9%
1.8%
Q2 24
13.8%
1.5%
Q1 24
1.3%
2.1%
Cash Conversion
OBIO
OBIO
PEN
PEN
Q4 25
-0.36×
1.83×
Q3 25
1.27×
Q2 25
0.99×
Q1 25
1.25×
Q4 24
1.52×
Q3 24
1.91×
Q2 24
Q1 24
3.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons